Hexapeptide-2

Hekisapepitaiti-2.

Hekisapepitaiti-2.

Tali vave

Reliable Hexapeptide-2 provided by professional manufacturer and factory. Offer wholesale skin repair hexapeptides for cosmetic formulation development, anti-aging skincare and biomedical laboratory research.

Hekisapepitaiti-2., or more commonly referred to as GHRP-6, is an α-melanocyte-stimulating hormone antagonist.

 

 

SKU: 198839 Fakakalakalasi:
Vahevahe ho'o 'ofa

Hekisapepitaiti-2., or more commonly referred to as GHRP-6., is an α-melanocyte-stimulating hormone antagonist. Inhibiting tyrosinase ngāue, it suppresses both the production and subsequent deposition of pigment; improving overall skin tone is one of its primary effects.

The incorporation of D-amino acids within its structure significantly enhances metabolic stability, along with strengthened receptor binding stability and affinity. Structurally similar to α-MSH itself, Hexapeptide-2 blocks this hormone’s ability to bind to its receptors – melanosaiti activity being the direct target inhibited.

As an equivalent of GHRP-6, pulsatile pituitary secretion of growth hormone is stimulated; fakatahataha'i 'o e polotini, bone development (and all related repair processes), fakamo'ui 'o e lavea, and enhancement of immune function are all positively influenced.

Fakahokohoko

Ko 'ene-Trp-'Ala-Trp-Phe-Lys pe H-'ene-D-Trp-'Ala-Trp-D-Phe-Lys-NH2.

Fika CAS

87616-84-0

Fomula Molekula

C46H56N12O6

Mamafa Molekula

873.014

Hexapeptide-2 Related Research

1.Ngaahi Faka'aonga'i Fakafaito'o 'e Malava

Promising cosmetological potential exists as a whitening agent or a therapeutic for various forms of hyperpigmentation disorders. The antagonistic properties also suggest broader potential uses: appetite stimulation, kakekisia improvement, and modulation of inflammation.

2.Antagonizing the α-MSH signaling pathway

Competitive receptor binding is the key mechanism; reducing melanini synthesis is the direct outcome.

Effective skin lightening is the end result of this process. Appetite centers in the hipotalamusi may be influenced, with quality of life improvements for patients with cachexia or age-related loss of appetite being a valuable secondary benefit.

3.Promoting Pulsatile Growth Hormone Secretion

Synergistic enhancement of endogenous ghrelin and suppression of somatostatin are what drive the desired pulsatile release.

This physiological pattern of release is considered a more effective therapeutic approach to avoid desensitization.

4.Stimulating Tissue and Bone Repair

Increased levels of growth hormone and IGF-1 promote mitotic and 'anaboliki ngāue, thereby stimulating tissue proliferation, fakafaikehekehe'i, and repair.

This accelerates the repair of soft tissue and bone, promotes fipolopalasi proliferation and kolaseni fakatahataha'i, and enhances wound healing.

Tānaki atu ki ai, ‘okú ne faka‘ai‘ai . osteoblast activity and bone matrix formation, which helps increase bone density, accelerate fracture healing, and combat age-related bone loss.

COA

HPLC

MS

Fakahokohoko:

Ko 'ene-Trp-'Ala-Trp-Phe-Lys pe H-'ene-D-Trp-'Ala-Trp-D-Phe-Lys-NH2.

CAS:

87616-84-0

M.W:

873.014 g/mol

Api Kumi Whatsapp Ngaahi Sevesi Koloa